Pfizer-BioNTech wins FDA approval for XFG-adapted 2026-2027 COVID vaccine in high-risk groups - PFE News | RalliesPfizer-BioNTech wins FDA approval for XFG-adapted 2026-2027 COVID vaccine in high-risk groups
P
PFE• FDA clears updated Comirnaty XFG vaccine
- FDA cleared Pfizer’s updated Comirnaty XFG COVID-19 shot for adults 65+.
- Authorization also covers ages 5-64 with at least one high-risk underlying condition.
- BioNTech partnered on the vaccine; U.S. shipments start immediately ahead of the 2026-2027 season.
•
